NICM
CGON icon

Neo Ivy Capital Management’s CG Oncology CGON Stock Holding History

Neo Ivy Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,758
Closed -$410K – 408
2025
Q2 		$410K Buy
+15,758
New +$380K 0.13% 205
2024
Q4 		– Sell
-29,678
Closed -$1.12M – 290
2024
Q3 		$1.12M Buy
+29,678
New +$1.04M 0.36% 112

Other funds holding CGON

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Neo Ivy Capital Management's CGON Position: Q3 2025 in Review

Neo Ivy Capital Management sold out of CG Oncology (CGON) in Q3 2025, closing a stake of 15,758 shares — an estimated $410K sold.

Neo Ivy Capital Management first reported a position in CGON in Q3 2024 and held it in 2 quarters. The position peaked at $1.12M in Q3 2024. 176 funds tracked by Wall St. Rank hold CGON as of Q3 2025.

  • Neo Ivy Capital Management reported no remaining CG Oncology position as of Q3 2025 after selling out during the quarter.
  • Neo Ivy Capital Management sold 15,758 CG Oncology shares in Q3 2025, an estimated $410K.
  • Neo Ivy Capital Management first reported a position in CG Oncology in Q3 2024 and held it in 2 quarters.
  • Neo Ivy Capital Management's CG Oncology position peaked at $1.12M in Q3 2024.
  • 176 funds tracked by Wall St. Rank held CG Oncology as of Q3 2025.

Based on Neo Ivy Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.